Frankfurt - Delayed Quote • EUR PureTech Health plc (0VQ0.F) Follow Compare 15.10 -0.10 (-0.66%) At close: January 24 at 8:18:32 a.m. GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) BOSTON, January 09, 2025--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference BOSTON, January 08, 2025--PureTech to present at 43rd annual J.P. Morgan Healthcare Conference. PureTech Appoints UBS as UK Corporate Broker BOSTON, January 06, 2025--PureTech Appoints UBS as UK Corporate Broker. PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial BOSTON, December 16, 2024--PureTech’s Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial With 71% institutional ownership, PureTech Health plc (LON:PRTC) is a favorite amongst the big guns Key Insights Institutions' substantial holdings in PureTech Health implies that they have significant influence over... PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 BOSTON, December 11, 2024--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting BOSTON, December 09, 2024--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting FTSE 100 reshuffle sees Vistry kicked out and Games Workshop join the UK blue-chip index Vistry and Frasers are among the stocks that will be relegated from the FTSE 100, while Games Workshop will be added to the UK blue-chip index. PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors BOSTON, November 20, 2024--PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer BOSTON, November 05, 2024--PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer PureTech to Present at Two Upcoming Investor Conferences BOSTON, October 30, 2024--PureTech to Present at Two Upcoming Investor Conferences PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round BOSTON, October 21, 2024--PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting BOSTON, October 09, 2024--PureTech Presents Research Highlighting Burden of IPF and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 PureTech to Present at CHEST 2024 Annual Meeting BOSTON, October 01, 2024--PureTech to Present at CHEST 2024 Annual Meeting PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults BOSTON, September 27, 2024--PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies BOSTON, September 06, 2024--PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies PureTech Health plc – Half-Year Report BOSTON, August 28, 2024--PureTech Health plc – Half-Year Report PureTech Appoints Michele Holcomb, PhD, to Board of Directors BOSTON, August 22, 2024--PureTech Appoints Michele Holcomb, PhD, to Board of Directors PureTech Health: Notice of Half-Yearly Results BOSTON, August 21, 2024--PureTech Health: Notice of Half-Yearly Results PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors BOSTON, August 13, 2024--PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors Performance Overview Trailing total returns as of 2025-01-24, which may include dividends or other distributions. Benchmark is FTSE 100 Return 0VQ0.F FTSE 100 YTD -12.21% +4.70% 1-Year -32.59% +13.58% 3-Year -58.29% +13.45%
